SCHEDULE 13G/A: Perceptive Advisors Discloses 4.4% Stake in Edgewise Therapeutics
Beneficial Ownership Report
Perceptive Advisors and related entities report a 4.4% beneficial ownership in Edgewise Therapeutics, holding 4,639,949 shares.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G.
- The Reporting Persons collectively beneficially own 4,639,949 shares of Common Stock of Edgewise Therapeutics, Inc.
- This ownership represents 4.4% of the outstanding Common Stock of Edgewise Therapeutics, Inc.
- The percentage is based on 105,345,708 shares of Common Stock outstanding as of July 31, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on August 7, 2025.
- Perceptive Life Sciences Master Fund, Ltd. directly holds all 4,639,949 shares.
- Perceptive Advisors LLC serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors.
- The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership, providing no explicit positive or negative sentiment regarding the company's operational or financial performance. It simply reports a significant institutional stake.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's future performance.
Industry Context
The filing indicates continued institutional interest in Edgewise Therapeutics, a biotechnology company. Significant stakes by specialized life sciences funds like Perceptive Life Sciences Master Fund can signal confidence in the company's pipeline or market position within the biotech sector.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by a prominent investment firm like Perceptive Advisors may be viewed positively, potentially signaling institutional confidence in Edgewise Therapeutics. This could influence market perception and investor sentiment.
- Company Management: Awareness of a significant institutional holder can influence strategic decisions and communication with the investment community.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires the filing of this statement. |
| 07/31/2025 | Date for which 105,345,708 shares of Common Stock outstanding were reported by the Issuer. |
| 08/07/2025 | Date Edgewise Therapeutics, Inc. filed its Quarterly Report on Form 10-Q, reporting shares outstanding. |
| 08/14/2025 | Date of signing for the Schedule 13G filing. |
Keywords
Edgewise Therapeutics, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Beneficial Ownership, Schedule 13G, Common Stock, Biotechnology Investment, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.